DOAC Dosing by Kidney Function: A CrCl Chart (2026)
- Kidney function drives dosing: every DOAC has renal cut-points because the kidneys clear part of each drug, measured by CrCl.
- Apixaban 2-of-3 rule: reduce to 2.5 mg twice daily in atrial fibrillation when at least two of these are true: age 80 or older, weight 60 kg or less, serum creatinine 1.5 mg/dL or higher.
- The reverse trap: edoxaban is contraindicated when CrCl is above 95 mL/min because it works less well there than warfarin.
Table of contents
By Vincent Couey, OmniRx founder. Source-cited from the FDA apixaban, rivaroxaban, edoxaban, and dabigatran prescribing information and NIH National Library of Medicine. Updated .
The direct oral anticoagulants replaced warfarin for most patients, but they traded one kind of monitoring for another: instead of frequent blood tests, they demand attention to kidney function, because each drug is cleared by the kidneys to a different degree. Getting the renal dose wrong cuts both ways. Too high a dose in someone with poor kidney function raises bleeding risk; too low a dose, or the wrong drug in someone with excellent kidney function, leaves the patient under-protected against stroke. This guide assembles the renal cut-points for all four major DOACs into one chart and explains the rules that trip people up, including the apixaban 2-of-3 criteria and edoxaban's unusual high-function contraindication. If you take more than one drug, screen the full list with the OmniRx Interaction Checker for interactions that also affect anticoagulant levels.
We cover the mechanism that links the kidney to dosing, the cross-DOAC chart, each drug's specific thresholds, and how prescribers reason about chronic kidney disease. This is reference, not a directive; the dose belongs with the prescriber.
Why does kidney function determine DOAC dosing?
Kidney function determines DOAC dosing because the kidneys remove a portion of each anticoagulant from the body, so weaker kidneys let the drug accumulate. Creatinine clearance is the standard estimate of that filtration rate, and it is the number on which every DOAC label hangs its dose-reduction thresholds.[1] Most thresholds apply to NVAF stroke prevention as set by the FDA. When CrCl falls, a fixed dose produces higher blood levels and more bleeding risk, which is why the labels lower the dose at defined cut-points rather than keeping one dose for everyone.
The amount each drug leans on the kidney varies widely, and that single fact explains most of the differences in the chart below. Dabigatran is roughly 80 percent renally cleared, so kidney changes move its levels the most; apixaban is the least renally dependent, which is why it is often chosen when kidney function is poor or unstable. The other two sit in between. The practical takeaway is that the same CrCl number means something different for each drug.
Is CrCl the same as eGFR?
Not exactly. DOAC labels were written around creatinine clearance estimated by the Cockcroft-Gault formula, while many lab reports show eGFR from a different equation, and the two can diverge at extremes of body size or age. For dosing decisions, prescribers generally use the Cockcroft-Gault CrCl the labels specify.
The cross-DOAC CrCl dosing chart
A cross-DOAC dosing chart lines up each anticoagulant's renal thresholds side by side so the differences are visible at a glance. The table below summarizes the FDA-labeled dosing in nonvalvular atrial fibrillation; it is a reference, not a prescription, and the prescriber applies it to the individual.
| DOAC | Renal clearance | Standard AF dose | Key CrCl rule |
|---|---|---|---|
| Apixaban (Eliquis) | ~27% | 5 mg BID | 2.5 mg BID if 2 of 3: age ≥80, weight ≤60 kg, SCr ≥1.5 |
| Rivaroxaban (Xarelto) | ~36% | 20 mg daily | 15 mg daily if CrCl 15-50; avoid if CrCl <15 |
| Edoxaban (Savaysa) | ~50% | 60 mg daily | Do NOT use if CrCl >95; 30 mg if CrCl 15-50 |
| Dabigatran (Pradaxa) | ~80% | 150 mg BID | 75 mg BID if CrCl 15-30; avoid if CrCl <15 |
How does the apixaban 2-of-3 rule work?
The apixaban 2-of-3 rule is the FDA-labeled trigger for cutting the apixaban dose in half for atrial fibrillation. The reduced dose of 2.5 mg twice daily applies when a patient meets at least two of three criteria: age 80 years or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher.[2] The structure is what people miss: a single criterion is not enough, so an 85-year-old with normal weight and normal creatinine stays on the full 5 mg twice daily, while an 85-year-old who also weighs under 60 kg drops to 2.5 mg.
| Criterion | Threshold | Counts toward reduction? |
|---|---|---|
| Age | 80 years or older | Yes, 1 of 3 |
| Body weight | 60 kg (132 lb) or less | Yes, 1 of 3 |
| Serum creatinine | 1.5 mg/dL or higher | Yes, 1 of 3 |
| Any one criterion alone | Only 1 met | No reduction |
| Any two or three | 2 or 3 met | Reduce to 2.5 mg BID |
Notice that the apixaban rule uses serum creatinine directly, not CrCl, which is the opposite of the other DOACs. That design makes apixaban simpler to dose when kidney estimates are uncertain, and it is one reason apixaban is so often chosen in older and frailer patients. The flip side is that the rule is easy to misapply by reducing on a single criterion, which under-doses the patient and leaves them less protected from stroke.
Why is edoxaban contraindicated at high CrCl?
Edoxaban is contraindicated in atrial fibrillation when creatinine clearance is above 95 mL/min because it prevents strokes less effectively than warfarin in that group. The FDA edoxaban label states it should not be used for stroke prevention in nonvalvular atrial fibrillation when CrCl is greater than 95 mL/min.[3] The reason is pharmacologic: people with very efficient kidneys clear edoxaban faster, so their blood levels run lower, averaging roughly 40 percent less than patients with moderately impaired function, which blunts its protective effect.
This is exactly the kind of detail that an interaction-and-dosing review is built to catch, because a patient switched between anticoagulants without a fresh look at kidney function can land on the wrong drug entirely. The same vigilance applies to the bleeding-risk side of anticoagulation, which our guide to pain relievers safe with Eliquis covers in depth.
How kidney-dependent are dabigatran and rivaroxaban?
Dabigatran is the most kidney-dependent DOAC and rivaroxaban sits in the middle, which shapes how each responds to declining renal function. Dabigatran (Pradaxa) is roughly 80 percent renally cleared, so the label reduces the dose to 75 mg BID when CrCl falls to 15-30 mL/min and generally advises against use below 15 mL/min.[4] Because so much of the drug rides on the kidney, an acute illness that drops kidney function can push dabigatran levels up quickly, which is why it is a riskier choice in patients with unstable renal function.
Rivaroxaban (Xarelto) is about 36 percent renally cleared, with the label calling for 15 mg once daily when CrCl is 15-50 mL/min and avoidance below 15 mL/min. A separate, easily forgotten rivaroxaban rule is that the 15 mg and 20 mg atrial-fibrillation doses must be taken with the evening meal to be absorbed properly, a non-renal detail that still affects how well the drug works. As always, these are reference thresholds; the prescriber sets the actual dose.
- Primary source
- FDA prescribing information for apixaban, rivaroxaban, edoxaban, and dabigatran (accessdata.fda.gov)
- Verified figures
- Apixaban 2-of-3 criteria; edoxaban CrCl >95 contraindication; dabigatran CrCl 15-30 reduction; rivaroxaban CrCl 15-50 reduction
- Corroboration
- NIH DailyMed labels; NIH/PMC DOAC pharmacology reviews
- Conflicts
- OmniRx earns ad and affiliate revenue; no specific paid product is recommended here
- Last verified
- May 29, 2026
Which DOAC is considered safest in CKD?
Apixaban is the DOAC most often favored in chronic kidney disease because it depends on the kidneys the least and has the most studied dosing across impaired renal function. With only about a quarter of the drug renally cleared, apixaban's blood levels move less when kidney function changes, which makes it a more forgiving choice when CKD is present or when renal function is unstable.[2] That said, "safest in CKD" is a population-level generalization, not an individual prescription, and the right drug depends on the whole picture.
Severe kidney impairment and dialysis are the hardest cases, where evidence is thinner and choices become specialist decisions that weigh stroke prevention against bleeding in a narrow margin. The practical move for patients is to make sure kidney function is checked before starting and rechecked periodically, because a dose that was correct last year may not be correct after a decline. Keeping the medication affordable also matters for staying on a consistent dose, which our friends at RxGrab address in their prescriptions-without-insurance guide.
Frequently asked questions
What is the apixaban 2-of-3 rule?
The apixaban 2-of-3 rule is the FDA-labeled criterion for reducing the apixaban dose to 2.5 mg twice daily in atrial fibrillation. The reduced dose applies when a patient meets at least two of these three criteria: age 80 years or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher. Meeting only one criterion does not trigger the reduction; meeting two or three does.
When is creatinine clearance too low for Eliquis?
Apixaban has been studied across a wide range of kidney function, including severe impairment and end-stage disease, which is part of why it is often considered among the more kidney-friendly DOACs. Dosing in severe impairment and dialysis is individualized and label- and guideline-dependent, so it is a prescriber decision rather than a simple cutoff. The 2.5 mg twice-daily reduced dose is driven by the 2-of-3 criteria, one of which is serum creatinine 1.5 mg/dL or higher.
What is the safest DOAC in chronic kidney disease?
There is no single answer for every patient, but apixaban is frequently favored in chronic kidney disease because it has the least renal clearance of the direct oral anticoagulants and the most studied dosing across impaired kidney function. Each DOAC has its own renal cut-points, and the choice depends on the individual's kidney function, weight, age, and other drugs. The decision belongs to the prescriber using current labels and guidelines.
Why is edoxaban contraindicated when CrCl is above 95?
The FDA edoxaban (Savaysa) label states it should not be used for stroke prevention in nonvalvular atrial fibrillation when creatinine clearance is greater than 95 mL/min, because in that population edoxaban was less effective than warfarin at preventing ischemic stroke. Edoxaban blood levels run lower in people with very good kidney function, which reduces its protective effect. This is the unusual case where too much kidney function, not too little, is the problem.
What is the dabigatran renal cutoff?
Dabigatran (Pradaxa) is the most kidney-dependent DOAC because roughly 80 percent of it is cleared by the kidneys. The FDA label provides reduced dosing in moderate-to-severe impairment and generally advises against use when creatinine clearance falls below 15 mL/min or in patients on dialysis outside specific labeled scenarios. Because so much of the drug depends on renal clearance, kidney function changes affect dabigatran more than the other DOACs.
The bottom line
Every direct oral anticoagulant doses by kidney function because the kidneys clear part of each drug, but the degree differs sharply: dabigatran is about 80 percent renally cleared while apixaban is the least kidney-dependent, which is why apixaban is so often chosen in chronic kidney disease. The apixaban 2-of-3 rule reduces the dose to 2.5 mg twice daily when at least two of age 80-plus, weight 60 kg or less, and serum creatinine 1.5 mg/dL or higher are met, and edoxaban is the outlier that is contraindicated above a CrCl of 95 mL/min because it underperforms warfarin there. Use the chart to understand the pattern, recheck kidney function over time, and let the prescriber set the dose. This is decision-support reference, not a directive.
- National Library of Medicine. Direct oral anticoagulants and renal dosing. NIH / PMC. ncbi.nlm.nih.gov verified 2026-05-29 return
- U.S. Food and Drug Administration. Eliquis (apixaban) Prescribing Information, Dosage and Administration. accessdata.fda.gov verified 2026-05-29 return
- U.S. Food and Drug Administration. Savaysa (edoxaban) Prescribing Information, Limitations of Use. accessdata.fda.gov verified 2026-05-29 return
- U.S. Food and Drug Administration. Pradaxa (dabigatran) Prescribing Information, Dosage and Administration. accessdata.fda.gov verified 2026-05-29 return